CO2021017737A2 - Composiciones y métodos para el tratamiento del dolor en sujetos con artritis reumatoide - Google Patents

Composiciones y métodos para el tratamiento del dolor en sujetos con artritis reumatoide

Info

Publication number
CO2021017737A2
CO2021017737A2 CONC2021/0017737A CO2021017737A CO2021017737A2 CO 2021017737 A2 CO2021017737 A2 CO 2021017737A2 CO 2021017737 A CO2021017737 A CO 2021017737A CO 2021017737 A2 CO2021017737 A2 CO 2021017737A2
Authority
CO
Colombia
Prior art keywords
pain
subjects
rheumatoid arthritis
compositions
treatment
Prior art date
Application number
CONC2021/0017737A
Other languages
English (en)
Inventor
Stefano Fiore
Susan Boklage
Toshio Kimura
John Gregory St
Wenhui Wei
Vivian Bykerk
Original Assignee
Regeneron Pharma
Sanofi Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma, Sanofi Biotechnology filed Critical Regeneron Pharma
Publication of CO2021017737A2 publication Critical patent/CO2021017737A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente divulgación se refiere al uso de un anticuerpo anti-receptor de IL6 para tratar un dolor inaceptable en sujetos con artritis reumatoide. Los sujetos con dolor inaceptable pueden tener, p. ej., dolor refractario o dolor refractario estricto
CONC2021/0017737A 2019-06-04 2021-12-23 Composiciones y métodos para el tratamiento del dolor en sujetos con artritis reumatoide CO2021017737A2 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962857247P 2019-06-04 2019-06-04
US201962930966P 2019-11-05 2019-11-05
EP20305191 2020-02-27
PCT/US2020/035871 WO2020247461A1 (en) 2019-06-04 2020-06-03 Compositions and methods for treating pain in subj ects with rheumatoid arthritis

Publications (1)

Publication Number Publication Date
CO2021017737A2 true CO2021017737A2 (es) 2022-05-20

Family

ID=71842803

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0017737A CO2021017737A2 (es) 2019-06-04 2021-12-23 Composiciones y métodos para el tratamiento del dolor en sujetos con artritis reumatoide

Country Status (14)

Country Link
US (1) US20200399380A1 (es)
EP (1) EP3980459A1 (es)
JP (1) JP2022534794A (es)
KR (1) KR20230061198A (es)
CN (1) CN115667301A (es)
AU (1) AU2020288561A1 (es)
BR (1) BR112021024445A2 (es)
CA (1) CA3142710A1 (es)
CO (1) CO2021017737A2 (es)
IL (1) IL288573A (es)
MA (1) MA56116A (es)
MX (1) MX2021014892A (es)
TW (1) TW202110892A (es)
WO (1) WO2020247461A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230399410A1 (en) * 2022-04-06 2023-12-14 Sanofi Biotechnology Compositions and methods for treating polymyalgia rheumatica by administering an il-6r antagonist

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5215534A (en) 1991-12-02 1993-06-01 Lawrence De Harde Safety syringe system
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
EP1912284B1 (en) 2005-07-29 2012-04-11 Fujitsu Ltd. Rf tag and rf tag manufacturing method
MY159787A (en) 2006-06-02 2017-01-31 Regeneron Pharma High affinity antibodies to human il-6 receptor
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
US9427531B2 (en) 2010-06-28 2016-08-30 Sanofi-Aventis Deutschland Gmbh Auto-injector
US9248242B2 (en) 2012-04-20 2016-02-02 Safety Syringes, Inc. Anti-needle stick safety device for injection device
US20140155827A1 (en) 2012-12-03 2014-06-05 Mylan, Inc. Medicament information system and method
US20170252434A1 (en) * 2014-09-16 2017-09-07 Sanofi Biotechnology Compositions for improving the health related quality of life of rheumatoid arthritis patients

Also Published As

Publication number Publication date
US20200399380A1 (en) 2020-12-24
JP2022534794A (ja) 2022-08-03
CA3142710A1 (en) 2020-12-10
BR112021024445A2 (pt) 2022-02-15
MX2021014892A (es) 2022-06-27
IL288573A (en) 2022-02-01
WO2020247461A1 (en) 2020-12-10
TW202110892A (zh) 2021-03-16
EP3980459A1 (en) 2022-04-13
MA56116A (fr) 2022-04-13
CN115667301A (zh) 2023-01-31
KR20230061198A (ko) 2023-05-08
AU2020288561A1 (en) 2021-12-23

Similar Documents

Publication Publication Date Title
CO2018004315A2 (es) Conjugados de 2-amino-pirrolo [3,2] pirimidina con anticuerpos anti-her-2
CO2021001912A2 (es) Composiciones anti-cd112r y métodos
CO2020016619A2 (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso
CL2022001271A1 (es) Agonista del receptor glp-1 y uso de este
CL2019001874A1 (es) Inhibidores de tgfß1 isoforma-específicos contexto-permisivos y uso de los mismos.
CL2018003096A1 (es) Receptor antigenico quimerico (car) con dominios de union a antigenos a la region constante del receptor de celulas t beta (divisional de la solicitud 2195-2016).
CL2019001740A1 (es) Novedoso conjugado de amanitina.
AR081750A1 (es) Anticuerpos anti-cd40
CR20180465A (es) Composiciones y métodos para tratar artritis reumatoide
CL2019002011A1 (es) Anticuerpos anti-tgf-beta y su uso.
CL2022001554A1 (es) Anticuerpos anti-mertk y métodos de uso de los mismos
CL2021002318A1 (es) Métodos de tratamiento de amiloidosis al
CO2021017737A2 (es) Composiciones y métodos para el tratamiento del dolor en sujetos con artritis reumatoide
MX2021012692A (es) Anticuerpos anti-mertk y sus metodos de uso.
BR112022009290A2 (pt) Terapia para malignidades de células hematopoiéticas com o uso de células t geneticamente modificadas visando cd70
AR119997A1 (es) Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecíficos anti-klk5 / klk7 y métodos de uso
PE20240638A1 (es) Anticuerpos anti-receptor de quimiocinas de motivo c-c 8 (ccr8) y metodos de uso
CL2021002807A1 (es) Anticuerpos y métodos para el tratamiento de la infección por influenza a
CO2022006014A2 (es) Terapia de tumores sólidos cd70+ utilizando linfocitos t genomodificados dirigidos a cd70 referencia cruzada a solicitudes relacionadas
DOP2022000129A (es) Anticuerpos contra la integrina alfa 11 beta 1
CL2020002622A1 (es) Anticuerpos anti-cd40 para uso en la prevención del rechazo de injertos
CO2021015660A2 (es) Métodos de diagnóstico y tratamiento de la artritis reuma-toide
CO2022017828A2 (es) Composiciones y métodos para el tratamiento del dolor no inflamatorio en sujetos con artritis reumatoide
CO2022009737A2 (es) Anticuerpos anti-ly6g6d y métodos de uso
CO2022000064A2 (es) Dosificación modificada de tocilizumab subcutáneo para la artritis reumatoide